ASH: With Yescar­ta lead­ing in ear­li­er-line lym­phoma, Bris­tol My­ers keeps the heat on with full da­ta for Breyanzi

Kick­ing off this week­end’s #ASH21, Gilead’s Kite and Bris­tol My­ers Squibb have re­leased com­pet­ing da­ta for their cur­rent-gen CAR-T drugs in sec­ond-line B cell lym­phoma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER